MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma—namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies—may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Stopfer, Lauren E., Rettko, Nicholas J., Leddy, Owen, Mesfin, Joshua M., Brown, Eric, Winski, Shannon, Bryson, Bryan, Wells, James A., White, Forest M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894220/
https://www.ncbi.nlm.nih.gov/pubmed/36454758
http://dx.doi.org/10.1073/pnas.2208900119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894220/
https://www.ncbi.nlm.nih.gov/pubmed/36454758
http://dx.doi.org/10.1073/pnas.2208900119

Ejemplares similares